Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has announced that the FDA has approved Mixject, the new delivery system for Trelstar, a palliative treatment for advanced prostate cancer.
Subscribe to our email newsletter
Mixject, developed and manufactured by Medimop Medical Projects, a subsidiary of West Pharmaceutical Services, is said to combine the proven efficacy of Trelstar Depot 3.75mg and Trelstar LA 11.25mg with new features that make preparation, administration and disposal easier.
These new features include a smaller 21-gauge needle for improved patient comfort, reconstitution without the use of a needle, and a shield covering the needle both before and after drug administration. The system is specifically designed to encourage compliance with OSHA (Occupational Safety and Health Administration) regulations within the medical community.